News

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

Immunovant, along with partner HanAll, will assess future plans for the development of batoclimab and provide an update at a future, unspecified date

MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).

Five-year pediatric Boston KPro results show vision gains, but low retention and high membrane, melt and glaucoma risks persist.

Bovelle reflects on the significance of this leadership milestone and shares her vision for mentorship, innovation, and global engagement across ophthalmology, optometry, and industry.

Regeneron announced that the FDA has amended the EYLEA HD label after the approval, adding 96-week results from the PULSAR wAMD trial and the PHOTON DME trial.

Biogen’s $5.6B Apellis deal boosts GA and renal complement therapies, spotlighting SYFOVRE benefits, safety signals, and future access.

Andrew G. Lee, MD, and Drew Carey, MD, review how clinical and imaging findings relate to vision recovery after radiotherapy for optic nerve sheath meningioma.

Images showed that Parkinson’s disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes.

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural disease progression in patients with ABCA4-associated retinopathy.

This study sheds light on the use of 0.05% atropine, which has been reported to be effective against myopia progression in some but not all studies.

The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001.

The formulation combines 2 pharmacologic agents: carbachol, a direct-acting cholinergic agonist, and brimonidine tartrate, an alpha-2 adrenergic receptor agonist.

The University of Rochester’s Flaum Eye Institute is embedding behavioral health into ophthalmology to improve patient care and clinician support.

In the JADE trial, OLN324 demonstrated numerically greater visual acuity gains and evidence of sustained retinal drying with fewer retreatments during a treatment-free follow-up period, compared with faricimab.

Kodiak Sciences has indicated plans to submit a biologics license application (BLA) to the US Food and Drug Administration.

Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Phase 3 shows epi-on oxygen CXL flattens pediatric keratoconus, improves vision, and stays well tolerated—now commercially available.

Luminopia, formerly cleared by the FDA for amblyopia in children, has begun its foray into IXT with positive data from a preliminary investigation.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

New MLSDT functional vision test tracks advanced retinitis pigmentosa better than acuity, supporting future gene and optogenetic therapy endpoints.